MDGL

379.1004.45%
WJ

William J. Sibold

CEO, President & Director

Mr. William J. Sibold, also known as Bill, serves as Chief Executive Officer, President and Director at Madrigal Pharmaceuticals, Inc. since September 8, 2023. Mr. Sibold joined Madrigal Pharmaceuticals, Inc. on September 8, 2023. He served as Head of Multiple Sclerosis and Senior Vice President at Sanofi-Aventis U.S. LLC. He served as President of Sanofi North America at Sanofi (Former Name: Sanofi-Aventis) since April 2021 until August 2023 and served as its Executive Vice President of Specialty Care at Sanofi since February 2020 until August 31, 2023. He was Senior Vice President and Head of Sanofi Genzyme’s Multiple Sclerosis, Oncology and Immunology organization at Genzyme Therapeutic Products Limited Partnership since January 2016 until June 2017. He was responsible for leading its Multiple Sclerosis Franchise, including the global commercialization of its two products. He served as Executive Vice President of Sanofi Genzyme at Sanofi since 2022 until August 2022. He served as Head of Multiple Sclerosis Business at Genzyme Corporation since November 10, 2011 until July 1, 2017 and served as its Senior Vice President until July 1, 2017. He was an Executive Vice President at Sanofi Genzyme Corporation at Sanofi since July 1, 2017 until February 2022. He has biopharmaceutical industry experience. Prior to joining Genzyme in 2011, he held various leadership positions, served as Chief Commercial Officer and Senior Vice President of Avanir Pharmaceuticals, Inc. from April 2011 to October 31, 2011. At Sanofi Genzyme, he led preparation for the global launches of dupilumab and Sarilumab. He served as the Chief Executive Officer and President of Lycera Corporation since January 2010. He served as the Managing Director of Biogen Idec's Asia Pacific region, where he was responsible for Australia, New Zealand and six Asian countries. He joined Sanofi in late 2011 as Head of the MS franchise, where he oversaw the successful launches of Aubagio® and Lemtrada®. He served as Senior Vice President, U.S. Neurology and Senior Vice President U.S. Commercial at Biogen Idec Inc. He has a proven track record of biopharmaceutical leadership, as well as business development and commercial expertise in several therapeutic areas, including inflammation. He started his career with Eli Lilly Canada in Sales. Mr. Sibold's experience also includes sales and marketing positions at Eli Lilly and Amgen Inc. At Amgen, he served as a Product Manager in Epogen Marketing responsible for developing product strategy, tactical plans and analytical decision-making. He has pharmaceutical and biotechnology experience with a focus on strategic planning, commercial operations, business development and general management. He held a number of leadership positions within Biogen, including driving their U.S. commercial operations in neurology, oncology and rheumatology and general management of Biogen’s Australian and Asia-Pacific business. He joined Biogen Idec Inc. as the Director of New Products Commercialization in 2001 where he was responsible for creating the commercial strategy and aligning stakeholder's opinions of the early stage pipeline. Next, he moved to Sydney to run Biogen Idec's Australia Asia Pacific business which included Australia, New Zealand and several Asian countries. During his tenure at Biogen Idec, he held multiple senior leadership roles at Biogen which included growing the U.S. commercial business (Rituxan, Avonex, Tysabri). He has also served as sponsor for North America since February 2020. He has been Director of Bioverativ Inc. since March 8, 2018. He served as Vice President of Commercial Operations for the Neurology Strategic Business Unit where he oversaw Sales, Marketing and Patient Services. From 1997 to 2001, he served in senior management positions at Innovative Clinical Solutions where he was instrumental in driving sales and business development initiatives. He served as a Director of Lycera Corporation. He relaunched Tysabri under a complicated Risk Minimization Plan mandated by the FDA and achieved significant sales growth milestones. He also was a Member of the varsity tennis team and captain in his senior year. He earned his MBA from Harvard Business School, Harvard University and received a Bachelor of Arts in Molecular Biophysics and Biochemistry from Yale University.

Positions